Search Results - chung-jen+(james)+chou

3 Results

Sort By:

Mitochondrial targeted HDAC inhibitors for the treatment of heart failure and related diseases and disorders (MitoDACs)

Technology: Researchers at MUSC have discovered HDAC1 is present in the adult cardiac myocyte mitochondria. A series of HDAC1 inhibitors that target mitochondria have been made (MitoDACs). One of the analogs, LL-66, localizes to the mitochondria and is absent from the nucleus in isolated adult rat cardiac myocytes. Inhibiting activity of HDAC1...

Published: 2/5/2023 | Updated: 2/5/2023 | Inventor(s): Donald Menick, Chung-Jen (James) Chou, Daniel Herr, Xiaoyang (李晓杨) Li

Keywords(s):

Category(s): BioPharma

Bi-Functional RGD Peptide and a Co-Signaling Mechanism to Promote Therapeutic Angiogenesis

Bi-Functional RGD Peptide to Promote Therapeutic Angiogenesis, Treat Ischemic Diseases Technology: While previous studies have focused on the identification of biological ligands to improve the functions of endothelial cells, MUSC and Clemson University researchers have combined modern bioinformatics and a newly established peptide functionalized...

Published: 2/5/2023 | Updated: 2/5/2023 | Inventor(s): Chung-Jen (James) Chou, Ying Mei, Jia Jia

Keywords(s):

Category(s): BioPharma

Novel class I HDAC inhibitors that are impervious to glucuronidation for the treatment of hematologic malignancies and inflammatory diseases/disorders

Novel class I HDAC inhibitors that are impervious to glucuronidation for the treatment of hematologic malignancies and inflammatory diseases/disordersTechnology: MUSC researchers have developed a series of potent and selective class I histone deacetylase (HDAC) inhibitors that do not suffer from the genotoxicity, off-target effects, and metabolic inactivation...

Published: 2/5/2023 | Updated: 2/5/2023 | Inventor(s): Chung-Jen (James) Chou, Jesse McClure, Cheng Zhang, Elizabeth Inks

Keywords(s):

Category(s): BioPharma